Evidence map›Paper›PMID 24663112›Full record

ArticleMarine drugs2014

Dereplication strategies for targeted isolation of new antitrypanosomal actinosporins A and B from a marine sponge associated-Actinokineospora sp. EG49.

Usama Ramadan Abdelmohsen, Cheng Cheng, Christina Viegelmann, Tong Zhang, Tanja Grkovic, Safwat Ahmed, Ronald J Quinn, Ute Hentschel, RuAngelie Edrada-Ebel

Abstract read
In one paragraph

Article in Marine drugs, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

81 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Biosynthesis and Characterization ofInternational journal of molecular sciences · 2024
    Article
  11. Article
  12. Metabolomic profile, anti-trypanosomal potential and molecular docking studies ofJournal of enzyme inhibition and medicinal chemistry · 2023
    Article
  13. Article
  14. Plants (Basel, Switzerland) · 2023
    Article
  15. Article
  16. Discovering New Natural Products Using Metabolomics-Based Approaches.Advances in experimental medicine and biology · 2023
    Article
  17. Article
  18. Review
  19. Article
  20. Article

21 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Usama Ramadan AbdelmohsenDepartment of Botany II, Julius-von-Sachs Institute for Biological Sciences, University of Würzburg, Julius-von-Sachs-Platz 3, Würzburg D-97082, Germany. usama.ramadan@uni-wuerzburg.de.
Cheng ChengDepartment of Botany II, Julius-von-Sachs Institute for Biological Sciences, University of Würzburg, Julius-von-Sachs-Platz 3, Würzburg D-97082, Germany. c.cheng@strath.ac.uk.
Christina ViegelmannStrathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, The John Arbuthnott Building, 161 Cathedral Street, Glasgow G4 0NR, UK. christina.viegelmann@strath.ac.uk.
Tong ZhangStrathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, The John Arbuthnott Building, 161 Cathedral Street, Glasgow G4 0NR, UK. tong.zhang.101@strath.ac.uk.
Tanja GrkovicEskitis Institute, Griffith University, Brisbane, QLD 4111, Australia. t.grkovic@griffith.edu.au.
Safwat AhmedDepartment of Pharmacognosy, Faculty of Pharmacy, Suez Canal University, Ismailia 41522, Egypt. safwat_aa@yahoo.com.
Ronald J QuinnEskitis Institute, Griffith University, Brisbane, QLD 4111, Australia. r.quinn@griffith.edu.au.
Ute HentschelDepartment of Botany II, Julius-von-Sachs Institute for Biological Sciences, University of Würzburg, Julius-von-Sachs-Platz 3, Würzburg D-97082, Germany. ute.hentschel@uni-wuerzburg.de.
RuAngelie Edrada-EbelStrathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, The John Arbuthnott Building, 161 Cathedral Street, Glasgow G4 0NR, UK. ruangelie.edrada-ebel@strath.ac.uk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High resolution Fourier transform mass spectrometry (HRFTMS) and nuclear magnetic resonance (NMR) spectroscopy were employed as complementary metabolomic tools to dereplicate the chemical profile of the new and antitrypanosomally active sponge-associated bacterium Actinokineospora sp. EG49 extract. Principal Component (PCA), hierarchical clustering (HCA), and orthogonal partial least square-discriminant analysis (OPLS-DA) were used to evaluate the HRFTMS and NMR data of crude extracts from four different fermentation approaches. Statistical analysis identified the best culture one-strain-many-compounds (OSMAC) condition and extraction procedure, which was used for the isolation of novel bioactive metabolites. As a result, two new O-glycosylated angucyclines, named actinosporins A (1) and B (2), were isolated from the broth culture of Actinokineospora sp. strain EG49, which was cultivated from the Red Sea sponge Spheciospongia vagabunda. The structures of actinosporins A and B were determined by 1D- and 2D-NMR techniques, as well as high resolution tandem mass spectrometry. Testing for antiparasitic properties showed that actinosporin A exhibited activity against Trypanosoma brucei brucei with an IC₅₀ value of 15 µM; however no activity was detected against Leishmania major and Plasmodium falciparum, therefore suggesting its selectivity against the parasite Trypanosoma brucei brucei; the causative agent of sleeping sickness.

Indexed as

ActinomycetalesAlginatesAlgorithmsAnimalsBenz(a)AnthracenesBiological AssayCell SurvivalCulture MediaFermentationGlucuronic AcidGlycosidesHexuronic AcidsLeishmania majorMagnetic Resonance SpectroscopyMass SpectrometryMetabolomicsactinosporin AAlginatesBenz(a)AnthracenesCulture MediaGlucuronic AcidGlycosidesHexuronic AcidsTrypanocidal Agents

Identifiers

PMID24663112
PMCPMC3967206

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.